GuideWhat is ergothioneine?Definition, transporter, food, human evidence and open questionsGuideBenefits and researchA claim-by-claim view of the evidenceResearchHealthy agingHuman and preclinical evidence for healthy-aging questionsResearchCognitive healthTrials and observational cognition researchGuideFood sourcesMushrooms and other dietary sourcesSafetyDosageResearch doses, commercial amounts and uncertaintySafetySafety and side effectsHuman safety evidence and unknownsBuyer guideSupplementsA neutral orientation to supplement formsBuyer guideHow to chooseTesting, source, COAs and cost per mg

Verified research record · Human observational

Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics

Cheah IK et al. · Antioxidants · 2022

Population
Older adults attending memory clinics in Singapore
Participants
470
Intervention
No intervention; baseline plasma ergothioneine
Duration
Up to 5 years
Topics
Human, Cognitive, Aging
PMID
36139790
DOI
10.3390/antiox11091716

Key finding

Lower baseline plasma ergothioneine was associated with poorer baseline performance and faster decline in several cognitive and functional measures.

Important limitations

Observational design cannot show that low ergothioneine caused decline or that supplementation would alter outcomes.

Editorial interpretation

Supports biomarker and intervention research, but not causal or treatment claims.

Funding and conflicts

See the publication’s complete funding and conflict disclosures.

Inspect on PubMed ↗Open DOI ↗